** Hikma Pharmaceuticals up c.3.9pct, top FTSE-100gainer & adds to huge gains from a day earlier after brokerageJefferies terms it its preferred name in the EMEA genericssector
** Brokerage bumps up stock to buy from hold and raises TPto 2615p from 2134p
** 8 of 13 brokerages rate the stock "buy" or higher, 4"hold" and 1 "sell" or lower; their median PT is $xx
** Jefferies terms deal for Boehringer Ingelheim's U.S.generic drugs business as a "game-changer" for Hikma in the U.S.and says it diversifies revenue base from 'specific marketopportunities' which have clouded visibility in the recent past
** Hikma on Tuesday agrees to buy Roxane for about $2.65billion in cash and stock
** More than two-thirds of daily average volume tradedwithin one and half hr of trading
** Till Monday's close, the stock has lost roughly 13percent since its inclusion in the index in March (RM: esha.vaish.thomsonreuters.com@reuters.net)